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A B S T R A C T
A simple and rapid method using liquid chromatography–mass spectrometry (LC-MS) for
the determination of metaxalone in human plasma has been developed and validated.
Letrozole was used as the internal standard (IS). The plasma samples were simply treated
with acetonitrile which allowed the precipitation of plasma proteins. The chromato-
graphic separation was achieved on a Sapphire C18 (2.1 mm × 150 mm, 5 μm, Newark, USA)
column using the mobile phase (5 mM ammonium acetate containing 0.01% formic acid:
acetonitrile (45:55, v/v)) at a flow rate of 0.3 ml/min. The selected ion monitoring (SIM) in
the positive mode was used for the determination of [M + H]+ m/z 222.1 and 286.1 for
metaxalone and letrozole, respectively. The standard curve obtained was linear (r2 ≥ 0.99)
over the concentration range of 30.24−5040 ng/ml. Meanwhile, no interfering peaks or matrix
effect was observed. The method established was simple and successfully applied to a phar-
macokinetic study of metaxalone in healthy Chinese volunteers after a single oral dose
administration of 800 mg metaxalone. The main pharmacokinetic parameters of metaxalone
were as follow: Cmax, (1664 ± 1208) ng/ml and (2063 ± 907) ng/ml; AUC0−36, (13925 ± 6590) ng/
ml h and (18620 ± 5717) ng/ml h; t1/2, (13.6 ± 7.7) h and (20.3 ± 7.7) h for the reference and
test tablets, respectively.These pharmacokinetic parameters of metaxalone in healthy Chinese
volunteers were reported for the first time.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Metaxalone, 5-[(3, 5-dimethylphenoxy) methyl]-2-oxazolidinone,
is a skeletal muscle relaxant and clinically used for relieving the
local muscle spasmodic pain caused by inflammation, trauma
and other musculoskeletal conditions [1]. Recently, some for-
mulations of metaxalone tablets were developed in China.
However, there is no pharmacokinetic study of metaxalone in
Chinese volunteers reported. It is meaningful to develop and
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validate a method for the determination of metaxalone in human
plasma which can be applied to the pharmacokinetic study.
By now, several analytical methods, such as reversed phase-
high performance liquid chromatography (RP-HPLC) [2] and
[3], UV-spectroscopy [4] and reversed phase–ultra perfor-
mance liquid chromatography (RP-UPLC) [5] have been reported
and used for the determination of metaxalone in bulk or solid
oral dosage-forms. Nirogi et al. [6] reported a liquid–liquid
extraction technique and Goswami et al. [7] reported a solid
phase extraction method for the determination of metaxalone
in human plasma by using LC-MS/MS. The sample prepara-
tions of these two methods are liquid–liquid extraction and
solid phase extraction, which are time-consuming, and the
extraction recoveries are relatively low. The aim of this study
was to develop and validate a time-saving method with simple
sample preparation procedures, and which can be applied to
the pharmacokinetic study of metaxalone in healthy Chinese
volunteers.
2. Materials and methods
2.1. Chemicals and reagents
Metaxalone reference standard (purity, 99.3%) was provided by
Frontage laboratories, Inc. (Suzhou, PR China). Letrozole (purity,
100.0%) was purchased from the National Institutes for Food
and Drug Control (Beijing, PR China). Acetonitrile and metha-
nol were of HPLC grade (Merck, Germany). Formic acid and
ammonium acetate were of analytical grade purity and were
purchased from Nanjing Chemical Reagent Co., Ltd. (Nanjing,
PR China). Ultra-pure water was made by Millipore water pu-
rification system (Millipore, Molsheim, France). Reference tablets
(SKELAXIN®, 800 mg) were purchased from King Pharmaceu-
ticals Inc. (USA) and test tablets (800 mg) were provided by ACTH
Pharma Tech (Shanghai) Co., Ltd. (Shanghai, PR China), which
were stored at 4 °C until use.
2.2. Instruments and analytical conditions
Chromatographic separation was performed using an Agilent
1100 Series system (Agilent Technologies, Palo Alto, CA, USA),
which includes an Agilent 1100 binary pump (model G1312A),
an Agilent 1100 auto-sampler (model G1067A) and a thermo-
stat column compartment (model G1330B). Chromatographic
separation was achieved on a Sapphire C18 (2.1 mm × 150 mm,
5 μm, Newark, USA) column using the mobile phase (5 mM am-
monium acetate containing 0.01% formic acid : acetonitrile
(45:55, v/v)) at a flow rate of 0.3 ml/min. The auto-sampler tem-
perature was kept at 10 °C, and 2 μl supernatant was injected
into LC-MS system.
The mass detection was achieved by using an Agilent
Technologies Series LC/MSD SL (Agilent Technologies, USA)
equipped with an electrospray ionization source. High purity ni-
trogen was used as the nebulizer and auxiliary gases. The
detection ions in the positive ionization mode for metaxalone
and letrozole were [M + H]+ m/z 222.1 and 286.1, respectively. Frag-
ment voltages of metaxalone and letrozole were set at 155V and
120V, respectively.
2.3. Preparation of stock solution, calibration standards
and quality control (QC) samples
Metaxalone and letrozole stock solutions were prepared in
methanol and were stored in −20 °C refrigerator. The working
solutions of metaxalone ranged 0.6048–100.8 μg/ml were pre-
pared by diluting the stock solution with methanol-water (50:50,
v/v) solution.The IS working solution (49.80 μg/ml) was prepared
with methanol. All working solutions were stored at −20 °C until
use. Calibration standards (30.24–5040 ng/ml) and quality control
(QC) samples (50.40, 504.0, 4032 ng/ml) were prepared by spiking
200 μl blank plasma samples with different volumes of working
solutions.
2.4. Sample preparation
Frozen human plasma samples were thawed at ambient tem-
perature. Aliquot of 200 μl plasma sample was added to 1.5 ml
polypropylene tube which containing 20 μl IS working solu-
tion (49.80 μg/ml) and vortex-mixed for 10 s. 600 μl aliquot of
acetonitrile was added into the tube and vortexed for 3 min
followed by a centrifugation at 15600 rpm for 5 min. 2 μl of su-
pernatant of each sample was injected into the LC-MS system.
2.5. Method validation
The method was validated according to the newest FDA guid-
ance for industry bioanalytical method validation, which was
validated through selectivity, linearity, sensitivity, accuracy and
precision, matrix effect, and recovery. Selectivity was as-
sessed by analyzing at least six different sources of blank
human plasma samples.
Linearity was verified in the plasma concentration range of
30.24–5040 ng/ml, and it was determined by weighted (1/C2,
r ≥ 0.99) least squares linear regression of calibration curve with
seven calibration standards. Sensitivity is defined as the lowest
analytical concentration which can be measured with accept-
able accuracy, precision and signal to noise ratio (S/N > 10). Inter-
day precisions and accuracy were determined by analyzing 5
replicates of LLOQ and QC samples on three consecutive days
(n = 15). The recovery and matrix effect were evaluated at three
QC concentration levels. The extraction recoveries were deter-
mined by comparing peak areas of metaxalone in plasma
samples at 3 QC levels (n = 5) which were spiked with the analyte
prior to extraction with those of samples to which the corre-
sponding solution was added after extraction. Matrix effect was
studied by calculating peak area ratios of metaxalone and
letrozole with matrix and without matrix. Matrix effect (ME) was
accepted if the coefficient variation (CV) of the peak area ratios
of metaxalone and letrozole did not exceed 15%. Stability of
metaxalone was evaluated with three replicates at concentra-
tion levels of 50.40, 4032 ng/ml. The stability tests of room
temperature stability (RTS), auto-sampler stability (ASS), freeze-
thaw stability (FTS) and long-term stability (LTS) were evaluated.
Short-term stability was performed by placing samples at room
temperature for 6 h. Long-term stability was assessed by freez-
ing samples at −20 °C for 30 d. Freeze-thaw stability was also
evaluated after three freeze-thaw cycles (room temperature to
−20 °C), and post-preparation stability of processed samples was
tested by placing it in an auto-sampler at 10 °C for 24 h.
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2.6. Pharmacokinetic study
The established and validated method was successfully applied
to a pharmacokinetic study of metaxalone in Chinese volun-
teers. Twelve healthy male Chinese volunteers aged 20–45
without history of cardiovascular, endocrine, gastrointesti-
nal, hematologic, hepatic, renal, and neuropsychosis were
recruited after a thorough medical, biochemical and physical
examination. All volunteers were given written informed
consent before participating in the study according to the
principles of the Declaration of Helsinki. This study was
designed as a randomized, crossover trial. Twelve healthy
volunteers were randomly assigned to take either reference
formulation or test formulation on the first day, and the
other formulation was taken after 7 d washout period. Volun-
teers were fasted for 10 h before administering metaxalone
tablets (800 mg) with 240 ml water. Water intake was allowed
at 2 h post-dose, and standard meals were provided at 4 h
and 10 h post-dose. Blood samples (3 ml) were collected into
heparin tubes at 0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 16, 24
and 36 h after dosing. The plasma samples were obtained by
centrifuging heparin tubes at 4000 rpm for 5 min and frozen
at −20 °C until analysis.
3. Results and discussion
3.1. Method development
The sample preparation procedures of liquid–liquid extrac-
tion [6] and solid phase extraction [7] for the determination
of metaxalone in human plasma are time-consuming and
the extraction recoveries are relatively low. It is meaningful
to develop a better method with simple sample handling
procedure and high extraction recovery to research pharma-
cokinetic characteristics of metaxalone in Chinese volunteers.
Plasma sample was simply treated with acetonitrile. In order
to enhance the sensitivity and avoid matrix effect, the com-
position of the mobile phase and the injection volume were
optimized. In order to achieve higher sensitivity and better
peak shape, different concentrations of formic acid (0.01%,
0.05%, 0.1%,) in water portion of the mobile phase were
optimized. It was found that 0.01% formic acid produced
highest sensitivity. After trying different concentrations of
ammonium acetate, 5 mM ammonium acetate solution con-
taining 0.01% formic acid produced higher response and
better peak shape. Matrix interference was inexistence when
the injection volume was set at 2 μl. Finally, the chromato-
graphic conditions of optimized mobile phase (5 mM
ammonium acetate solution containing 0.01% formic acid : ace-
tonitrile (45:55, v/v)) and 2 μl injection volume were adopted.
The mass spectrum conditions were then optimized and it
was found that the best detection was produced when the
parameters of drying gas flow, nebulizer pressure, drying gas
temperature, and capillary voltage, were set at 12 l/min,
50 psi, 350 °C, and 4000 V, respectively. The full-scan ion
mass spectra (Fig. 1) shows two peak signals [M + H]+ m/z
222.1 and 286.1 of metaxalone and letrozole, respectively,
which are selected as detection ions.
3.2. Assay validation
3.2.1. Selectivity
The selectivity of the method was proved by comparing SIM
chromatograms of the blank plasma sample, blank plasma
sample spiked with metaxalone and the IS and a plasma sample
obtained from volunteers after oral administration of
metaxalone tablets. The corresponding chromatograms are
showed in Fig. 2. The retention time of metaxalone and the
IS were 2.9 and 2.8 min, respectively. No interference was found
in all plasma samples.
Fig. 1 – Full-scan mass spectra of (A) metaxalone and
(B) letrozole.
Table 1 – Intra-day and inter-day precision and accuracy
of metaxalone in human plasma (n = 5).
Concentration
(ng/ml)
RSD (%) RE (%)
Added Measured
(mean ± SD)
Intra-day Inter-day Accuracy
30.24 31.82 ± 1.29 3.8 5.5 5.2
50.40 51.43 ± 2.61 4.3 8.2 2.0
504.0 534.8 ± 19.3 3.2 5.3 6.1
4032 4200 ± 206 5.2 2.9 4.2
The data are given as mean ± SD; RSD: relative standard deviation;
RE: relative error.
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3.2.2. Linearity, LLOQ, accuracy and precision
Calibration curves over the concentration range of 30.24 to
5040 ng/ml were linear with correlation coefficient r ≥ 0.99. The
typical regression equation of the calibration curve was
f = 0.0008∙C − 0.0034. The intra-day and inter-day results of pre-
cision and accuracy are summarized in Table 1. The data
demonstrate that the precision and accuracy values are within
the acceptable criteria.
3.2.3. Extraction recovery and matrix effect
The mean extraction recoveries at three QC levels (50.40, 504.0,
4032 ng/ml) were as follows: 98.6% ± 4.4%, 93.4% ± 2.7%,
96.1% ± 1.5%, respectively. The mean recovery of the IS was
96.3% ± 1.9%. Matrix effects of the six different sources of blank
plasma on metaxalone at three QC levels (50.40, 504.0,
4032 ng/ml) were as follows: 98.7% ± 4.7%, 105.1% ± 2.1%,
105.6% ± 2.2%, respectively.
3.2.4. Stability
The stability investigations of room temperature stability (RTS),
auto-sampler stability (ASS), freeze–thaw stability (FTS) and
long-term stability (LTS) were performed, and the results are
summarized in Table 2. The data indicate that metaxalone is
stable enough during sample preparation and storage
conditions.
3.2.5. Pharmacokinetic study
The developed and validated method was successfully applied
to the pharmacokinetic study of metaxalone in twelve healthy
male Chinese volunteers after oral administrating metaxalone
tablets (800 mg). The pharmacokinetic parameters were calcu-
lated by DAS 3.2.5.The mean plasma concentration-time curves
of the reference tablets and test tablets are shown in Fig. 3. The
values of the main pharmacokinetic parameters (Cmax, AUC0−36,
AUC0−∞, t1/2, Tmax,) are given in Table 3. All the reported pharma-
cokinetic parameters of metaxalone for the reference tablets in
humans are listed in Table 4. The main pharmacokinetic pa-
rameters of metaxalone in Chinese volunteers obtained in this
study (see Table 3) are almost consistent with those in Ameri-
can after oral administrating SKELAXIN® tablets (800 mg) under
fasted conditions [8]. Compared to the high fat conditions [7]
Fig. 2 – Typical chromatograms of metaxalone and the IS in
human plasma samples. (A) Blank plasma sample;
(B) a blank plasma sample spiked with metaxalone
(30.24 ng/ml) and the IS (49.80 μg/ml); and (C) a plasma
sample obtained from a volunteer at 2 h after oral
administration one SKELAXIN® tablet (800 mg).
Table 2 – Stability of metaxalone in human plasma
(n = 3).
Conditions Concentration
(ng/ml)
RE
(%)
RSD
(%)
Added Measured
(mean ± SD)
6 h at room
temperature
50.40 52.78 ± 1.40 4.7 2.7
4032 4036 ± 4 0.1 0.1
24 h in the
auto-sampler
50.40 49.66 ± 1.34 −1.5 2.7
4032 4089 ± 13 1.4 0.3
Three
freeze-thaw cycles
50.40 51.44 ± 2.20 2.1 4.3
4032 4349 ± 229 7.9 5.3
30 day at −20 °C 50.40 47.85 ± 2.10 −5.1 4.4
4032 4302 ± 14 6.7 0.3
The data are given as mean ± SD; RSD: relative standard deviation;
RE: relative error.
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and [8], the measured values of pharmacokinetic parameters
(Cmax,AUC0−36,AUC0−∞) are relatively lower under the fasting con-
dition, which implied that the pharmacokinetic characteristics
of metaxalone are significantly affected by food.
4. Conclusion
In summary, a new simple and reproducible LC-MS method for
the determination of metaxalone in human plasma has been
validated. It was successfully applied to the pharmacokinetic
study in healthy male Chinese volunteers. The developed
method has advantages of simple sample preparation proce-
dure and high extraction recovery. The pharmacokinetic
parameters of metaxalone in healthy Chinese volunteers were
reported for the first time.
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Fig. 3 – Mean plasma concentrations-time profile of
metaxalone in Chinese healthy volunteers after oral
administration metaxatone tablets (800 mg). Data are
means ± SD, n = 12.
Table 3 – Pharmacokinetic parameters of metaxalone
measured in Chinese volunteers.
Parameters Reference Test
Mean SD RSD
(%)
Mean SD RSD
(%)
C max (ng/ml) 1664 1208 72.6 2063 907 43.9
AUC0−t (ng/ml∙h∙) 13925 6590 47.3 18620 5717 30.7
AUC0−∞ (ng/ml∙h) 15917 7387 46.4 19977 5029 25.2
t1/2 (h) 13.6 7.7 56.9 20.3 7.7 63.5
T max (h) 4.8 2.9 60.1 5.0 2.7 54.3
The data are given as mean; SD: standard deviation; RSD: relative
standard deviation.
Table 4 – Reported pharmacokinetic parameters of
metaxalone in human after oral dose administration of
the reference tablets (SKELAXIN®, 800 mg).
Parameters American [8] Indian [7]
Fasted High fat meal High fat meal
C max (ng/ml) 1816 3510 3246
AUC0−t (ng/ml∙h) 14531 20683 16922
AUC0−∞ (ng/ml∙h) 15045 20833 30170
T max (h) 3.0 4.9 –
The data are given as mean.
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